Kunal Malhotra, MD
Nephrology · St. Louis, MONPI 1720236904
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Vifor Pharma, Inc. accounts for 60.8% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $6,987, more than ten times the $403 reported in 2019. Among nephrology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $298.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$11K
- Fresenius USA Marketing, Inc.$4K
- Calliditas Therapeutics US Inc.$2K
- AstraZeneca$340
- Amgen$205
- Travere Therapeutics, Inc.$200
- plus $574 from 12 others
What the payments were for
- Consulting fees$4,10022%
- Speaking & faculty fees$9,19850%
- Travel & lodging$2,72015%
- Food & beverage$2,10512%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 17 | $11,086 |
| Fresenius USA Marketing, Inc. | 5 | $3,694 |
| Calliditas Therapeutics US Inc. | 4 | $2,124 |
| AstraZeneca(2 entities) | 5 | $340 |
| Amgen(2 entities) | 3 | $205 |
| Travere Therapeutics, Inc. | 8 | $200 |
| Mallinckrodt Enterprises LLC | 1 | $100 |
| GSK | 1 | $97 |
| Baxter Healthcare | 2 | $67 |
| Akebia Therapeutics Inc | 4 | $61 |
| Novartis | 2 | $52 |
| Medtronic | 1 | $44 |
| Otsuka America Pharmaceutical, Inc. | 3 | $41 |
| Chiesi USA, Inc. | 1 | $31 |
| Vantive US Healthcare LLC | 1 | $27 |
| Sanofi | 1 | $25 |
| Veloxis Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,223 in reported general payments places this provider in the 90th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 62 | $12,628 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $10,196 |
| Clonidine | 33 | $4,818 |
| Calcitriol | 197 | $3,069 |
| Nifedipine ErNifedipine | 85 | $1,910 |
| Calcium Acetate | 42 | $1,441 |
| Bumetanide | 60 | $1,168 |
| Potassium Chloride | 59 | $1,143 |
| Chlorthalidone | 57 | $890 |
| Allopurinol | 130 | $748 |
| Torsemide | 33 | $638 |
| Potassium Citrate ErPotassium Citrate | 14 | $583 |
| Losartan Potassium | 91 | $503 |
| Mirtazapine | 13 | $442 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma | $340 | $10,19616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 253 nephrology providers in Missouri.
Other nephrology in St. Louis
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
- Bahar BastaniSt Louis$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.